WEDBUSH SECURITIES INC - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 180 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2020. The put-call ratio across all filers is 1.51 and the average weighting 0.0%.

Quarter-by-quarter ownership
WEDBUSH SECURITIES INC ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2020$274,000
-11.0%
6,611
+3.0%
0.03%
-10.3%
Q2 2020$308,000
-17.0%
6,420
+114.7%
0.03%
-12.1%
Q4 2019$371,000
-29.6%
2,990
-62.3%
0.03%
-36.5%
Q3 2019$527,000
-5.0%
7,936
+13.7%
0.05%
-7.1%
Q2 2019$555,000
-4.3%
6,979
+34.5%
0.06%
-9.7%
Q1 2019$580,000
+26.4%
5,189
+13.9%
0.06%
+5.1%
Q4 2018$459,000
+4.6%
4,554
+31.1%
0.06%
+18.0%
Q3 2018$439,000
+67.6%
3,474
+11.5%
0.05%
+56.2%
Q2 2018$262,000
-25.6%
3,117
-45.5%
0.03%
-30.4%
Q1 2018$352,000
+6.3%
5,722
+0.9%
0.05%
+15.0%
Q4 2017$331,000
+14.1%
5,672
+136.8%
0.04%
+5.3%
Q2 2017$290,000
+22.9%
2,395
+14.9%
0.04%
+18.8%
Q1 2017$236,000
-8.5%
2,085
-12.0%
0.03%
-15.8%
Q4 2016$258,000
-31.7%
2,370
+3.3%
0.04%
-32.1%
Q3 2016$378,000
+17.4%
2,295
+1.5%
0.06%
+5.7%
Q2 2016$322,000
+13.0%
2,260
+1.8%
0.05%
+6.0%
Q1 2016$285,000
-8.9%
2,220
+6.0%
0.05%
-12.3%
Q4 2015$313,000
-12.6%
2,095
-3.0%
0.06%
-20.8%
Q3 2015$358,000
-31.5%
2,160
-0.4%
0.07%
-25.8%
Q2 2015$523,000
-13.4%
2,168
+1.3%
0.10%
-5.8%
Q1 2015$604,000
+74.6%
2,140
-3.4%
0.10%
+94.3%
Q4 2014$346,0002,2150.05%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q4 2020
NameSharesValueWeighting ↓
Chicago Capital Management, LLC 185,781$4,611,56512.16%
Samsara BioCapital, LLC 640,688$11,878,3563.64%
ALPINE ASSOCIATES MANAGEMENT INC. 2,203,295$40,849,0892.14%
Versor Investments LP 378,480$7,017,0191.42%
Magnetar Financial LLC 2,407,209$44,629,6551.14%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 2,077,893$38,524,1360.85%
Fort Baker Capital Management LP 430,600$7,983,3240.74%
EHP Funds Inc. 84,210$1,561,2530.73%
Terrapin Asset Management, LLC 30,000$556,2000.63%
AQR Arbitrage LLC 734,970$13,626,3440.61%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders